TLSA Stock — Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd (TLSA)

Updated October 16, 2026.

TLSA is a Stock. Its deepest 1-year drawdown was 61.9%.

Tiziana Life Sciences Ltd is a biopharmaceutical company focused on developing therapies for neurodegenerative and neuroinflammatory diseases, with lead candidates including Foralumab, a monoclonal antibody in Phase II trials for multiple sclerosis and neurological conditions, and TZLS-501 for autoimmune and inflammatory diseases. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to clinical-stage biotechnology development rather than current income.

TLSA performance

Returns are updating. TLSA's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 61.9%.

TLSA key facts

Asset type

Stock

Asset class

Equity

Inception date

11/20/2018

Distribution frequency

None

Last close

$1.05 (as of 2026-10-16)

Market cap

$133,622,088

Average volume

558773.0

Beta

0.44

Payout ratio

0.0%

EPS

$-0.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TLSA risks and drawbacks

The deepest 1-year drawdown on record here is 61.9%.

Who may consider TLSA — and who may not

It is a weaker fit for investors who need monthly cash flow (TLSA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TLSA

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions